Sanofi

Sanofi-aventis

Lead Pharma Holding B.v.

Synthelabo

Sanofi-synthelabo

Lead Pharma B.v.

David Machnik

Yannick Evanno

Laurent Dubois

Catherine Gille

Andre Malanda

Nathalie Rakotoarisoa

Joseph Maria Gerardus Barbara Cals

Jean-Francois Sabuco

Sander Bernardus Nabuurs

Danielle De Peretti

Pascal George

Mireille Sevrin

Luc Even

André Malanda

Daniele De Peretti

Philippe Michel Manoury

Laurent Schio

Patrick Andre Lardenois

Antonio Almario Garcia

Benoit Marabout

Jean-Pierre Merly

Michel Peynot

Arlette Tixidre

Jocelyne Roy

Jean Francedillaois Gibert

Nathalie Rakotoarisoa-Rameix

Jean-François Sabuco

Joseph Maria Cals

Dubois Laurent

The present application relates to compounds according to (Formula IA) or (Formula IB):  The compounds can be used as inhibitors of ROR&#x3b3; and are useful for the treatment of ROR&#x3b3; mediated diseases.

ROR gamma (ROR&#x3b3;) modulators

Novel compounds according to Formula I Meta or para or a pharmaceutically acceptable salt thereof wherein:A-Aare N or CR, CR, CR, CR, respectively, with the proviso that no more than two of the four positions A in A-Acan be simultaneously N; A, A, A, A, Aare N or CR, CR, CR, CR, CR, respectively, with the proviso that at least one but no more than two of the five positions A in A, A, A, A, Ais N; Ris C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; Ris H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; the sulfonyl group with Ris represented by one of R, Ror R; Ris H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; and Ris C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.

The invention relates to compounds of the general formula (I): Wherein X, Y, Z, Z, Z, Z, Zand n are as defined herein. The invention also relates to a method for making the same and to the use thereof in therapy.

[object Object]

Compounds of formula (I): wherein R, R, R, R, Het and X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof

The invention concerns compounds of general formula (I): Wherein n, X, X, X, X, Y, Z, Z, Z, Zand Zare as defined herein. The invention also concerns a process for the preparation of compounds of formula (I) and their therapeutic use.

N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof

The disclosure relates to compounds of formula (I): wherein X, X, X, X, Z, Z, Z, Z, Ra, Rb, n, Y, and W are as defined in the disclosure, or a salt thereof, or a hydrate or solvate thereof, and to processes for the preparation of these compounds and the therapeutic use thereof.

Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof

Compounds of formula (I): wherein R, R, R, R, Rand X are as defined in the disclosure, or an acid addition salt thereof, and the therapeutic use and process of synthesis thereof.

The invention concerns tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R, Rand Rare as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.

The invention relates to compounds of the general formula (I):  Wherein X, Y, Z, Z, Z, Z, Zand n are as defined herein. The invention also relates to a method for making the same and to the use thereof in therapy.

N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy

The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R, Rand Rare as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.

Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use

N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof

8-azabicyclo&lsqb;3.2.1&rsqb; octane-3-methanamine derivatives as ligands of D2 and D3 dopamine and 5HT1A and 5HT2 serotonin receptors

Growing community of inventors

Paris, France

David Machnik